/PRNewswire/ Late-breaking pivotal data show significant disease improvements in eosinophilic esophagitis and also in chronic spontaneous urticaria 18.
/PRNewswire/ Late-breaking pivotal data show significant disease improvements in eosinophilic esophagitis and also in chronic spontaneous urticaria 18.
A new medication has been added to the treatment options for children with moderate-to-severe asthma. In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11.
email article
Among children with uncontrolled, moderate-to-severe asthma, treatment with the biologic dupilumab (Dupixent) was associated with a reduction in exacerbation and improvements in lung function in phase III findings from the international VOYAGE trial.
Evidence of lung function improvement occurred within 2 weeks of treatment initiation, and was sustained during the 52-week randomized, placebo-controlled trial.
Compared with the placebo group, dupilumab-treated children (ages 6 to 11 years) showed a 59% reduction in exacerbations, along with improvements in forced expiratory volume (FEV
1) and reduced airway inflammation, as measured by fractional exhaled nitric oxide (FeNO), reported VOYAGE lead researcher Leonard Bacharier, MD, of Vanderbilt University Medical Center in Nashville.